STOCK TITAN
  1. Home
  2. Financials
  3. NIKA

Nika Pharmaceuticals Financials

NIKA
Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Nika Pharmaceuticals (NIKA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NIKA FY2025

External financing is funding recurring cash burn while liabilities and negative equity outpace the company's liquid resources.

In FY2025, financing inflow of $79K almost matched operating cash burn of -$80K, so outside capital was mainly replacing cash consumed by operations rather than adding financial flexibility. That is why cash still shrank from $20K in FY2023 to $2K in FY2025 even as funding continued.

The FY2025 net loss of -$76K was close to the cash outflow from operations of -$80K, which means the reported deficit is translating into real cash use rather than being driven by large non-cash items. With total assets of only $21K, even modest overhead consumes a large share of the balance sheet.

Negative equity widened from -$82K in FY2023 to -$298K in FY2025, showing that obligations have been compounding faster than the asset base is being rebuilt. The current ratio also slipped from 0.2x to 0.07x, so short-term liquidity became tighter rather than stabilizing.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 0 / 100
Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Nika Pharmaceuticals's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity
0

Nika Pharmaceuticals's current ratio of 0.07 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak
1/9

Nika Pharmaceuticals passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality
1.04x

For every $1 of reported earnings, Nika Pharmaceuticals generates $1.04 in operating cash flow (-$80K OCF vs -$76K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
N/A
Net Income
-$76K

Nika Pharmaceuticals reported -$76K in net income in fiscal year 2025.

EPS (Diluted)
$0.00

Nika Pharmaceuticals earned $0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$2K
YoY-9.3%
5Y CAGR+3.2%

Nika Pharmaceuticals held $2K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
876M
YoY-16.4%

Nika Pharmaceuticals had 876M shares outstanding in fiscal year 2025. This represents a decrease of 16.4% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
N/A

NIKA Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue N/A N/A N/A N/A N/A N/A N/A $156
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $3K N/A $4K-72.7% $14K+694.4% $2K N/A $6K-16.0% $8K
Operating Income -$13K N/A -$8K+56.5% -$18K-42.0% -$13K N/A N/A -$22K
Interest Expense N/A N/A N/A N/A N/A N/A N/A N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income -$13K N/A -$8K+56.5% -$18K-42.0% -$13K N/A N/A -$22K
EPS (Diluted) $0.00 N/A $0.00 $0.00 $0.00 N/A $0.00 $0.00

NIKA Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $21K-1.7% $21K-11.1% $24K-25.3% $32K-9.7% $35K+95.1% $18K+1193.9% $1K-99.6% $390K
Current Assets $21K-1.7% $21K-11.1% $24K-25.3% $32K-9.7% $35K+95.1% $18K+1193.9% $1K-99.4% $222K
Cash & Equivalents $2K-19.0% $2K-70.0% $6K-59.7% $16K-18.4% $19K+818.7% $2K+50.3% $1K-81.5% $7K
Inventory N/A N/A N/A N/A N/A N/A N/A $14K
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A $196K
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $332K+4.1% $319K+12.1% $284K0.0% $284K+5.6% $269K+12.5% $239K+18.5% $202K-68.3% $637K
Current Liabilities $332K+4.1% $319K+12.1% $284K0.0% $284K+5.6% $269K+12.5% $239K+13.8% $210K-67.0% $637K
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity -$311K-4.5% -$298K-14.2% -$261K-3.2% -$253K-7.8% -$234K-5.9% -$221K-10.4% -$200K+4.0% -$209K
Retained Earnings -$9.0M-0.1% -$9.0M-0.4% -$9.0M-0.1% -$9.0M-0.2% -$8.9M-0.1% -$8.9M-0.1% -$8.9M+0.5% -$9.0M

NIKA Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow -$13K+65.6% -$39K-316.5% -$9K+49.6% -$19K-43.1% -$13K+54.3% -$28K N/A -$34K
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow $13K-62.3% $34K $0-100.0% $15K-50.0% $30K+3.4% $29K+480.0% $5K+14.3% $4K
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

NIKA Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A -14395.5%
Net Margin N/A N/A N/A N/A N/A N/A N/A -14395.5%
Return on Equity N/A N/A N/A N/A N/A N/A N/A N/A
Return on Assets -64.7% N/A -33.9%+24.3pp -58.1%-21.2pp -37.0% N/A N/A -5.8%
Current Ratio 0.060.0 0.07-0.0 0.08-0.0 0.11-0.0 0.13+0.1 0.07+0.1 0.01-0.3 0.35
Debt-to-Equity -1.070.0 -1.07+0.0 -1.09+0.0 -1.13+0.0 -1.15-0.1 -1.08-0.1 -1.01+2.0 -3.05
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$298K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.07), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Elite Pharmaceuticals Inc ELTP
$376.9M
Trulieve Cannabis Corp TCNNF
$1.4B
Green Thum GTBIF
$1.6B
Glass House Brands Inc GLASF
$863.0M
Curaleaf Hldgs CURLF
$2.6B

Frequently Asked Questions

No, Nika Pharmaceuticals (NIKA) reported a net income of -$76K in fiscal year 2025.

Nika Pharmaceuticals (NIKA) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nika Pharmaceuticals (NIKA) generated -$80K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Nika Pharmaceuticals (NIKA) had $21K in total assets as of fiscal year 2025, including both current and long-term assets.

Nika Pharmaceuticals (NIKA) had 876M shares outstanding as of fiscal year 2025.

Nika Pharmaceuticals (NIKA) had a current ratio of 0.07 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Nika Pharmaceuticals (NIKA) had a debt-to-equity ratio of -1.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Nika Pharmaceuticals (NIKA) had a return on assets of -363.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Nika Pharmaceuticals (NIKA) had $2K in cash against an annual operating cash burn of $80K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Nika Pharmaceuticals (NIKA) has negative shareholder equity of -$298K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Nika Pharmaceuticals (NIKA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Nika Pharmaceuticals (NIKA) has an earnings quality ratio of 1.04x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Nika Pharmaceuticals (NIKA) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top